Pharma News in Global Health and Sustainability - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma News in Global Health and Sustainability
A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 9, Issue 8

GlaxoSmithKline (GSK) and Save the Children have launched a $1- million Healthcare Innovation Award to identify and reward innovations in healthcare which have proven successful in reducing child deaths in developing countries. From June 27 to August 26, 2013, organizations from across the developing world can nominate examples of innovative healthcare approaches they have discovered or implemented. These approaches must have resulted in tangible improvements to under-age-five child survival rates, be sustainable, and have the potential to be scaled-up and replicated. Co-chaired by Sir Andrew Witty, CEO of GSK, and Justin Forsyth, CEO of Save the Children, the judging anel, made up of experts from the fields of public health, science and academia, will award $250,000 to the best healthcare innovation to further progress their work. An additional $750,000 is available for runners-up awards. The award will also provide a platform for winning organizations to showcase their innovations and share information to enable others with an interest in improving healthcare to adapt and replicate successful interventions and create more positive change for children in their own country and beyond.

Sanofi and GDF SUEZ, an energy firm, have signed an agreement to strengthen their collaboration for implementing projects in the field of energy at Sanofi industrial sites. The five-year contract includes mainly renewable energy production and distribution systems. Building on an initial agreement signed in March 2012 for Europe and Turkey, the two groups have expanded their collaboration to include sites in the United States, Canada, Mexico, Brazil, China, and Singapore. All Sanofi’s production lines will be included: chemicals, pharmaceuticals, vaccines, biotechnology, and animal health. The initial three-year term contract is extended to five years.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here